Petrie-Flom Welcomes New Precision Medicine Fellow!

Petrie-Flom Center, August 16, 2018

We are excited to announce that Sara Gerke is joining the Petrie-Flom Center's Project on Precision Medicine, Artificial Intelligence, and Law (PMAIL) as our Precision Medicine Fellow. As the…

Read More

We Have to Be Smart About Artificial Intelligence in Medicine: When the technology is complicated, opaque, changing, and absolutely vital to the health of a patient, how do we make sure it works as promised?

Slate, August 15, 2018
W. Nicholson Price II (Academic Fellow Alumnus)

From the article: For millions of people suffering from diabetes, new technology enabled by artificial intelligence promises to make management much easier. Medtronic’s Guardian Connect system promises to alert users 10 to 60 minutes before they hit…

Read More

Drug Pricing Policy: HHS Introduces Step Therapy In Medicare Advantage

Health Affairs Blog, August 14, 2018
Rachel E. Sachs (Academic Fellow Alumna)

From the post:  Last Tuesday, the Centers for Medicare and Medicaid Services (CMS) took its latest action in the area of drug pricing. CMS gave Medicare Advantage (MA) plans the ability to use step therapy, in which a patient may be required by their…

Read More

The Trump admin has another pretty good, pretty modest plan to lower drug costs

Vox, August 13, 2018
Dylan Scott, quoting Rachel E. Sachs (Academic Fellow Alumna)

From the article: “My concern is that once again, the administration’s rhetoric is out of step with its actual policy moves,” Sachs said. “The administration…

Read More

Katie Kraschel Named One of ABA’s Top 40 Young Lawyers

Solomon Center for Health Law and Policy at Yale Law School, August 9, 2018
Honoring Katie Kraschel (Student Fellow Alumna)

Katie Kraschel, Executive Director of the Solomon Center for Health Law and Policy,  has been named among the American Bar Association’s “Top 40 Young Lawyers” for 2018. The…

Read More

Report blames gaming of patent system for high drug prices: Most drugs named are biologics, and manufacturing trade secrets make competition especially tricky, legal expert says.

Med City News, August 9, 2018
Alaric Dearment, quoting W. Nicholson Price II (Academic Fellow Alumnus)

[...] The report, “Overpatented, Overpriced: How Excessive Pharmaceutical Patenting is Extending Monopolies and Driving up Drug Prices,” was released last week by the nonprofit Initiative for Medicines, Access and Knowledge, also known as I-MAK. The report found that the 12 highest-grossing…

Read More

CMS’ plan to lower drug spending in Medicare Advantage

Politico Pulse, August 8, 2018
Brianna Ehley, quoting Rachel E. Sachs (Academic Fellow Alumna)

From the article: Some viewed the step as a bit of a letdown, since HHS Secretary Alex Azar has been touting more sweeping changes to drug prices in Medicare Part B, like letting the private sector insurance plans negotiate the costs of the drugs in fee-for-service…

Read More

Here’s what’s behind the ads accusing Bob Hugin of ‘killing off cancer patients’, August 7, 2018
Herb Jackson, quoting Rachel E. Sachs (Academic Fellow Alumna)

From the article: "They're resorting to tactics the FDA criticized. Under the guise of patient safety, this is really about preserving a monopoly position," said law professor Rachel…

Read More

To Tame Prescription Prices, HHS Dips A Toe Into Drug Importation Stream

Kaiser Health News, August 1, 2018
Rachel Bluth, quoting Rachel E. Sachs (Academic Fellow Alumna)

From the article: This isn’t the first time officials have suggested importing drugs from other countries to find better prices. Bills have been offered in Congress to allow it, and George W. Bush administration officials investigated the issue and produced…

Read More

Penn State forms addiction legal resources team at Dickinson Law

Penn State News , July 30, 2018
Kristie Auman-Bauer, featuring Matthew Lawrence (Academic Fellow Alumnus)

From the article:  CARLISLE, Pa. — With the number of opioid overdose deaths continuing to rise in Pennsylvania, a group of Penn State Dickinson Law students and faculty are becoming advocates and providing resources for those who are affected by addictions. …

Read More

A Fear of Lawsuits Really Does Seem to Result in Extra Medical Tests

The New York Times, July 23, 2018
Margot Sanger-Katz, featuring Michael Frakes (Academic Fellow Alumnus)

From the article:  Mr. Gruber and Michael D. Frakes, a Duke economist and lawyer, looked at the health care system for active-duty members of the military. Under longstanding law, such patients get access to a government health care system but are barred from…

Read More

The Health 202: This mother’s tweet about drug prices went viral. Trump’s plans are unlikely to help

Washington Post, July 24, 2018
by Colby Itkowitz, quoting Rachel Sachs (Academic Fellow Alumna)

From the article: “It’s going to take a lot of time and there's a lot of hurdles in the way, but that’s not what you want to explain when you want to show how you’re lowering drug prices,” he told me. “Ultimately they are going…

Read More

Unpacking the bold — and the bluster — in Trump’s plan to bring down drug prices

STAT, July 23, 2018
by Erin Mershon, quoting Rachel Sachs (Academic Fellow Alumna)

From the article: The administration says the proposal will save Medicare money, which could translate into lower premiums. It will also mean lower co-pays for any beneficiary who might need a new drug when it first comes onto the market, since those payments are…

Read More

The Trump administration finally has one good idea to lower drug prices

Vox, July 20, 2018
by Dylan Scott, quoting Rachel Sachs (Academic Fellow Alumna)

From the article: Right now, in the above circumstances and when there isn’t an actual drug shortage, “we don’t have a good policy solution,” Scott Gottlieb, the FDA commissioner, told me Thursday in a brief phone interview.

Read More

Update: UK Ministers Quit Over Brexit

BBC, July 9, 2018
Interview featuring Rachel Sachs (Academic Fellow Alumna)

From the interview: We consider the implications for Brexit as two senior UK ministers resign. David Henig is UK director of the European Centre For International Political Economy. He explains why this could be just the start of a government crisis. President…

Read More

HHS forced to choose migrants over medicines

Politico, July 18, 2018
By Dan Diamond, quoting Rachel Sachs (Academic Fellow Alumna)

From the article: Echoing the pharma industry, Verma stressed that the state's request violated current law — the first time she's publicly cited a legal defense. “f you want to go forward with negotiating with…

Read More

What Pfizer, Trump, and consumers got out of a surprising deal — and what they didn’t

STAT, July 11, 2018
By Erin Mershon and Ike Swetlitz, quoting Rachel Sachs (Academic Fellow Alumna)

From the article: After months of pledging he would get pharmaceutical companies to lower their prices, President Trump can now say that he pressed the CEO of a major drug maker, Pfizer, to back down on a series of price hikes.

Read More

The Health 202: ‘ACA’ removed from swaths of website, watchdog reports

Washington Post, July 12, 2018
By Colby Itkowitz, quoting Rachel Sachs (Academic Fellow Alumna)

From the article: As The Post’s Damian Paletta also noted, the announcement was an example of Trump’s successful use of the presidential bully pulpit. “This is not an industry that compromises,” Rachel Sachs, an associate professor…

Read More

The News on Drug Prices? Nothing Good

The New York Times, July 17, 2018
By The Editorial Board, quoting Rachel Sachs (Academic Fellow Alumna)

From the article: “It takes away a substantial tool that a lot of states were hoping to use,” says Rachel Sachs, a law professor and drug policy expert at Washington University in St. Louis. It also points to a hypocrisy, she says. “They’re…

Read More

Pro-ACA group: Court pick Kavanaugh refused to uphold pre-existing condition ban

PolitiFact, July 18, 2018
By Jon Greenberg, quoting Allison K. Hoffman (Academic Fellow Alumna)

From the article: For the makers of the ad, this is very simple. "Two judges upheld the Affordable Care Act and its patient protections, and he declined to uphold it," Demand Justice executive director Brian Fallon said. "He could…

Read More